Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors

NCT07403721 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07403721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07403721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Recruiting
Start date
April 8, 2026
Completion date
February 1, 2032
Enrollment
464 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or locally advanced solid tumors with microsatellite instability-high (msi-h) or mismatched repair deficiency (dmmr)